Early Phase 2 trial data have generated significant clinical interest, but retatrutide has not yet received MHRA or EMA authorisation and remains confined to research settings
If more than four days have passed, skip it and take your next dose on the regular day
keep out of reach of young children contra-indication If you have a medical condition, are pregnant, lactating, or trying to conceive, are under the age of 18, or are taking medications, consult your health care practitioner before using this product
Brandsborg, P
Risk of bias assessment The Cochrane Collaborations risk of bias tool was employed to assess the risk of bias for each study (Reference Higgins, Altman and Gtzsche19)
As AOD9604 is similar enough in structure to natural HGH it appears to avoid the bodys immune system response and there is no evidence the body forms antibodies against it